A clinical trial to study the impact of low dose radiation to the lungs in patients with moderate COVID Pneumonia.

Phase 2

• Conditions: Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: D- Radiation Therapy

• Registration Number: CTRI/2021/06/033912
• Lead Sponsor: All India Institute of Medical Sciences Patna

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1)Age >= 18 years

2)Patients with confirmed diagnosis of SARS-Cov2 infection by RT-PCR on nasopharyngeal swab and / or bronchoalveolar lavage (BAL)

3)Patients having MOHFW Moderate disease with SpO2 < 94% on Room Air and Respiratory rate > 20 Breaths per minute on Room Air with fewer than 8 days of symptom onset and currently receiving standard medication for COVID-19 at appropriate doses. Covid-19 classification criteria led down by MOHFW, Govt. Of India (Appendix 1)

4)Suggestive picture finding for interstitial pneumonia on chest X-ray and / or chest CT (optional)

5)Ability to understand and sign informed consent.

6)Ability to acquire and maintain the set-up necessary for the delivery of radiotherapy treatment

Exclusion Criteria

1)Patients with MOHFW defined severe disease.

2)Patients undergoing invasive mechanical ventilation.

3)Patients with active autoimmune systemic diseases.

4)Hemodynamically unstable patients.

5)Patients with a positive pregnancy test.

6)Impossibility to maintain the set-up necessary for radiotherapy treatment.

Study & Design

• Study Type: Interventional
• Study Design: Not specified